Enhancement of bioavailability of perinodopril using lipid based nanaocarrier mediated oral drug delivery system

Mahesh Pg; I. Somasundaram

doi:10.53730/ijhs.v6nS3.7893

Enhancement of bioavailability of perinodopril using lipid based nanaocarrier mediated oral drug delivery system

https://doi.org/10.53730/ijhs.v6nS3.7893

Authors

Mahesh Pg
pgmahesh83@gmail.com
Research scholar, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Pallavaram, Chennai 600117, Tamilnadu, India
I. Somasundaram Associate Professor, Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Pallavaram, Chennai 600117, Tamilnadu, India

Keywords:

perinodopril, antihypertensive, NLC, lipid nanoparticles, carriers

Abstract

Hypertension is a serious cardiovascular event which refers to rise in the arterial blood pressure. Perinodopril which has been classified as calcium channel blocker is utilized in the treatment of hypertension. Perinodopril comes under BCS class II drug (low solubility/high permeability) which shows variable absorption pattern due to solubility limitation. Therefore, nanostructured lipid carrier (NLC) of Perinodopril was developed which is suitable for drug with high log P value as it offers the advantage of high drug entrapment and loading capacity to lipophilic drugs. Tween 80 and Poloxamer 188 were reportedly P-gp efflux inhibitors which would be an added feature to the property of Perinodopril -NLC thus enhancing drug availability across intestine. Therefore, the objectives of the present work were to develop an optimized Perinodopril -NLC using Quality by design (QbD) and evaluating it for enhancement in intestinal uptake and solubilisation fate (in physiologically simulating gastro intestinal milieu) of Perinodopril which would further enhance the oral bioavailability. Physicochemical characterization of the drug by means of UV spectra, DSC and FT-IR concluded that Perinodopril is pure and authentic. Both medium chain triglycerides (MCT) and long chain triglycerides (LCT) were used in the solubility studies of Perinodopril.

Downloads

Download data is not yet available.

References

ACE 2 modulator [Onli-ne]. Available from: http://www.apeiron- biologics.com, 08:42, 14 Apr 2016.

Adis Insight [Online]. Available from: http://adisinsight.springer.com/drugs/80 0003008, 07:10, 12 Apr 2016.

Akbarzadeh A, Samiei M and Davaran S. Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale Res Lett., 7(1):144, 2012.

Ambrisentan - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) [Online], Available from: www.reuters.com, 09:45, 11 Apr 2016.

Andersen K. Aldosterone Synthase Inhibition in Hypertension. Curr Hypertens Rep, 15(5):484-488, 2013.

Ansari KA, Pagar KP, Anwar S and Vavia PR. Design and optimization of self-microemulsifying drug delivery system (SMEDDS) of felodipine for chronotherapeutic application. Braz J Pharm Sci, 50:203-212, 2014.

Antal I, Kubovcikova M, Zavisova V, Koneracka M, Pechanova O, Barta A, Cebova M, Antal V, Diko P, Zduriencikova M and Pudlak M. Magnetic poly (D,L-lactide) nanoparticles loaded with aliskiren: A promising tool for hypertension treatment. J Magn Magn Mater, 380: 280-284, 2015.

Anuradha K and Kumar MS. Development of Lacidipine loaded nanostructured lipid carriers (NLCs) for bioavailability enhancement. Int. J. Pharm. Med. Res, 2(2):50-57, 2014.

Aronow WS. Treatment of systemic hypertension. Am J Cardiovasc Dis, 2(3):160-170, 2012.

Arora A, Shafiq N, Jain S, Khuller GK and Sharma S. Development of Sustained Release “NanoFDC (Fixed Dose Combination)” for Hypertension – An Experimental Study. PLoS ONE, 10(6): e0128208, 2015.

Published

25-05-2022

How to Cite

Pg, M., & Somasundaram, I. (2022). Enhancement of bioavailability of perinodopril using lipid based nanaocarrier mediated oral drug delivery system. International Journal of Health Sciences, 6(S3), 7992–7999. https://doi.org/10.53730/ijhs.v6nS3.7893

Download Citation

Issue

Vol. 6 No. S3 (2022)

Section

Peer Review Articles

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.

Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.